Immunize.org supports evidence-based vaccination recommendations and schedules. Read more at About Us.

Issue Number 48             January 21, 1999

CONTENTS OF THIS ISSUE

  1. Epivir-HBV (lamivudine) is approved by the FDA as oral treatment for chronic hepatitis B

----------------------------------------------------------

Back to Top

(1)
January 21, 1999
EPIVIR-HBV (LAMIVUDINE) IS APPROVED BY THE FDA AS ORAL TREATMENT FOR CHRONIC HEPATITIS B

On December 9, 1998, the FDA approved the first oral, anti-viral medication for the treatment of adults with chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation. Epivir-HBV, a brand name for lamivudine, is available as a tablet and as an oral solution.

Epivir-HBV is manufactured by Glaxo Wellcome, Inc., based in Research Triangle Park, North Carolina.

For additional information about Epivir-HBV, read the package insert.

About IZ Express

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .

Our Affiliated Sites

For the Public: VaccineInformation.org
For Coalitions: ImmunizationCoalitions.org
Let's Get Real
Information about pediatric vaccines for parents and providers.
65+ Flu Defense
Protect vulnerable, older adult patients from influenza.
Give2MenACWY.org
Improve protection from meningococcal serogroups ACWY.
NAIIS
Home of the National Adult and Influenza Immunization Summit.